The Latin America, Middle East and Africa Live Biotherapeutic Products And Microbiome CDMO Market should witness market growth of 50.9% CAGR during the forecast period (2023-2029).
The market is also developing as a result of the rising incidence of chronic diseases as well as the rising desire for personalized medication. These complicated medicines need to be developed and manufactured, and CDMOs with competence in these domains have the infrastructure and know-how to support such efforts. As a consequence, pharmaceutical and biotech businesses can delegate production to CDMOs, freeing up their resources for R&D.
In addition, there has been an increase in study on naturally occurring pharmaceuticals (LBPs) and the microbiota as possible therapeutic agents, which has led to an increase in research & development in these areas. This has increased the need for CDMOs with experience in these areas. The microbiome and its function in health and illness are now better understood because of developments in bioinformatics and sequencing technologies. This has made it possible to create microbiome-based medicines and more specialized, effective live biotherapeutic solutions.
According to the international diabetes federation (IDF), in 2021, 73 million persons (20-79) had diabetes in the Middle East and North Africa region. It is predicted that this number will rise to 136 million by 2045. Additionally, 27 million adult patients with diabetes are undiagnosed, accounting for 38% of the region's total adult patients with the disease. Impaired glucose tolerance (IGT), which puts people at higher risk of type 2 diabetes, affects 48 million adults in this region. In 2021, diabetes caused the death of approximately 796,000 individuals. As a result, there is a greater need for therapeutic interventions for the treatment of diseases like diabetes. Therefore, the presence of a significant patient base, along with improving healthcare infrastructure and disposable incomes, is driving the development of the market in the LAMEA region.
The Brazil market dominated the LAMEA Live Biotherapeutic Products And Microbiome CDMO Market by Country in 2022, thereby, achieving a market value of $1,486.2 Thousands by 2029. The Argentina market is experiencing a CAGR of 51.7% during (2023-2029). Additionally, The UAE market would exhibit a CAGR of 50.5% during (2023-2029).
Based on Application, the market is segmented into C.difficile, Crohns Disease, IBS, Diabetes, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Arranta Bio Holdings, LLC (Recipharm AB) (EQT AB), Cerbios-Pharma SA, Biose Industrie, List Biological Laboratories, Inc., AcuraBio Pty Ltd (Ampersand Capital Partners), Wacker Chemie AG (Dr. Alexander Wacker Familiengesellschaft mbH), Quay Pharmaceuticals Ltd (SGS S.A.), BiomX, Inc., Lonza Group AG, and 4D Pharma Plc.
The market is also developing as a result of the rising incidence of chronic diseases as well as the rising desire for personalized medication. These complicated medicines need to be developed and manufactured, and CDMOs with competence in these domains have the infrastructure and know-how to support such efforts. As a consequence, pharmaceutical and biotech businesses can delegate production to CDMOs, freeing up their resources for R&D.
In addition, there has been an increase in study on naturally occurring pharmaceuticals (LBPs) and the microbiota as possible therapeutic agents, which has led to an increase in research & development in these areas. This has increased the need for CDMOs with experience in these areas. The microbiome and its function in health and illness are now better understood because of developments in bioinformatics and sequencing technologies. This has made it possible to create microbiome-based medicines and more specialized, effective live biotherapeutic solutions.
According to the international diabetes federation (IDF), in 2021, 73 million persons (20-79) had diabetes in the Middle East and North Africa region. It is predicted that this number will rise to 136 million by 2045. Additionally, 27 million adult patients with diabetes are undiagnosed, accounting for 38% of the region's total adult patients with the disease. Impaired glucose tolerance (IGT), which puts people at higher risk of type 2 diabetes, affects 48 million adults in this region. In 2021, diabetes caused the death of approximately 796,000 individuals. As a result, there is a greater need for therapeutic interventions for the treatment of diseases like diabetes. Therefore, the presence of a significant patient base, along with improving healthcare infrastructure and disposable incomes, is driving the development of the market in the LAMEA region.
The Brazil market dominated the LAMEA Live Biotherapeutic Products And Microbiome CDMO Market by Country in 2022, thereby, achieving a market value of $1,486.2 Thousands by 2029. The Argentina market is experiencing a CAGR of 51.7% during (2023-2029). Additionally, The UAE market would exhibit a CAGR of 50.5% during (2023-2029).
Based on Application, the market is segmented into C.difficile, Crohns Disease, IBS, Diabetes, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Arranta Bio Holdings, LLC (Recipharm AB) (EQT AB), Cerbios-Pharma SA, Biose Industrie, List Biological Laboratories, Inc., AcuraBio Pty Ltd (Ampersand Capital Partners), Wacker Chemie AG (Dr. Alexander Wacker Familiengesellschaft mbH), Quay Pharmaceuticals Ltd (SGS S.A.), BiomX, Inc., Lonza Group AG, and 4D Pharma Plc.
Scope of the Study
By Application
- C.difficile
- Crohns Disease
- IBS
- Diabetes
- Others
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Arranta Bio Holdings, LLC (Recipharm AB) (EQT AB)
- Cerbios-Pharma SA
- Biose Industrie
- List Biological Laboratories, Inc.
- AcuraBio Pty Ltd (Ampersand Capital Partners)
- Wacker Chemie AG (Dr. Alexander Wacker Familiengesellschaft mbH)
- Quay Pharmaceuticals Ltd (SGS S.A.)
- BiomX, Inc.
- Lonza Group AG
- 4D Pharma Plc
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. LAMEA Live Biotherapeutic Products And Microbiome CDMO Market by Application
Chapter 4. LAMEA Live Biotherapeutic Products And Microbiome CDMO Market by Country
Chapter 5. Company Profiles
Companies Mentioned
- Arranta Bio Holdings, LLC (Recipharm AB) (EQT AB)
- Cerbios-Pharma SA
- Biose Industrie
- List Biological Laboratories, Inc.
- AcuraBio Pty Ltd (Ampersand Capital Partners)
- Wacker Chemie AG (Dr. Alexander Wacker Familiengesellschaft mbH)
- Quay Pharmaceuticals Ltd (SGS S.A.)
- BiomX, Inc.
- Lonza Group AG
- 4D Pharma Plc
Methodology
LOADING...
